Theoretical stack · Performance & Muscle

CJC-1295 + Ipamorelin

The canonical GH-axis combination

Promising

Theoretical educational discussion

This page summarizes a peptide combination as discussed in the research and user communities. It does not constitute medical advice, dosing recommendations, or instructions for personal use. Combination-specific human RCT evidence is generally absent for these stacks; per-compound evidence does not transfer additively to combinations.

Decisions about peptide therapy require an appropriately licensed clinician. We do not sell peptides.

At a glance

The most-discussed growth-hormone-axis combination. CJC-1295 (typically the no-DAC "Mod GRF 1-29" variant) provides GHRH-receptor priming; ipamorelin provides selective ghrelin-receptor stimulation. Together they are designed to mimic a physiologic GH pulse.

Compounds in the stack

Each compound's role in the combination, with link to its full peptide page for the underlying research.

CJC-1295

GHRH analog. The no-DAC variant produces brief GHRH-receptor priming aligned with a single GH pulse; the with-DAC variant produces sustained tonic elevation

Half-life: 30 min (no DAC) / 6–8 days (with DAC)

Ipamorelin

Selective ghrelin/GHS-R agonist that triggers GH release without significant cortisol or prolactin elevation seen with older GHRPs

Half-life: ≈ 2 hours

Mechanistic rationale

The two-receptor approach is the basis of the stack. GH release is regulated by two pituitary inputs: GHRH (positive signal from the hypothalamus) and ghrelin (synergistic GH-secretagogue signal). Combining a GHRH analog with a ghrelin-receptor agonist produces a larger, cleaner GH pulse than either alone — the synergy is biochemically real and has been demonstrated in pituitary cell-culture and human pharmacology studies.

The community preference is typically the no-DAC CJC-1295 (Mod GRF 1-29) + ipamorelin pairing. The no-DAC variant produces a discrete pulse, mimicking physiologic GH secretion patterns, while ipamorelin amplifies the pulse without adding cortisol or prolactin elevation. The with-DAC variant produces sustained elevation, which some argue overrides natural pulsatile signaling.

Human and emerging evidence

The peer-reviewed literature on this combination is summarized below across two tiers — controlled human research (the highest standard) and preclinical / animal-model evidence.

Human research

The combination-specific human evidence is limited; per-compound human data is more substantial:

CJC-1295 with DAC — Phase 1 and 2 studies (Teichman 2006, Ionescu 2006) demonstrated dose-dependent IGF-1 elevations of 1.5–3× over 6 days in healthy adults.
Ipamorelin — characterized in human pharmacology studies showing reliable GH peaks with minimal cortisol/prolactin effects compared to older GHRPs (GHRP-6, hexarelin).
The combination is widely used in research-peptide protocols and clinical anti-aging settings, but published combination-specific RCTs of body-composition or functional outcomes are essentially absent.

Per-compound effects on biochemistry (raising GH and IGF-1) are well-established; what those biochemical effects mean for body composition, recovery, or longevity in healthy adults is the open question.

Reported user experiences

The reports below are aggregated from research forums, podcasts, and user-community discussions. They are useful as hypothesis-generating signals but are not controlled clinical data — selection bias, placebo response, and underreporting of adverse effects all apply.

The CJC + ipamorelin combination is one of the most popular GH-axis protocols in user communities. Common reports:

Improved sleep depth (particularly with bedtime dosing of the no-DAC variant).
Subjective recovery improvements between training sessions.
Modest fat loss / body-recomposition effects over months.
Skin and connective-tissue quality changes in some users.
Some users report fluid retention, carpal-tunnel-like numbness or tingling, and reduced insulin sensitivity with prolonged use — all consistent with GH-axis activation.

Potential benefits and risks

Potential benefits

Two-receptor synergy is mechanistically validated and reproducible
Ipamorelin's selectivity avoids cortisol/prolactin elevations of older GHRPs
No-DAC dosing pattern preserves physiologic pulsatility
Per-compound human pharmacology is well-characterized

Potential risks

No combination-specific RCT evidence for functional outcomes
Sustained IGF-1 elevation has theoretical cancer-risk associations (epidemiologic data; mechanistic plausibility)
Reduced insulin sensitivity with chronic use
Water retention and carpal-tunnel-like symptoms reported
Banned by WADA (GH secretagogues are prohibited at all times)
Source variability in research-peptide markets

Open questions

Does the GH pulse magnitude translate to clinically meaningful body-composition or recovery outcomes in healthy adults?
What is the long-term cancer-risk profile of sustained IGF-1 elevation in this magnitude?
Is no-DAC pulsatile dosing meaningfully different from with-DAC sustained elevation in long-term safety?

The takeaway

The CJC-1295 + ipamorelin combination has the cleanest mechanistic story in the GH-axis peptide world — two-receptor synergy is biochemically real and reproducible, and ipamorelin's selectivity is a genuine improvement over the older GHRPs. The honest gap is that biochemical GH/IGF-1 elevation does not automatically translate into the body-composition, recovery, and anti-aging outcomes that drive online interest. For readers tracking this combination, the calibration is: real pharmacology, modest expected effects, attention to long-term IGF-1 and metabolic considerations.

References

Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
Raun K, et al. Ipamorelin, the first selective GH secretagogue. Eur J Endocrinol. 1998;139(5):552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone in response to CJC-1295. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018652/